|Bid||1.8700 x 3200|
|Ask||1.9400 x 1200|
|Day's Range||1.7900 - 1.9400|
|52 Week Range||0.9500 - 3.9500|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.17|
DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020.
DURECT Corporation (Nasdaq: DRRX) today announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as well as information on DURECT' investigational drug candidate, DUR-928, being developed for the treatment of AH. The webinar will be held on Friday, November 20, 2020 at 1:00 pm Eastern Time. Dr. Sussman will be available to answer questions following the formal presentations.
DRRX earnings call for the period ending September 30, 2020.